Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Other Non-Current Assets (2020 - 2021)

SAB Biotherapeutics' Other Non-Current Assets history spans 2 years, with the latest figure at $13.1 million for Q4 2021.

  • For Q4 2021, Other Non-Current Assets rose 5471.24% year-over-year to $13.1 million; the TTM value through Dec 2021 reached $13.1 million, up 5471.24%, while the annual FY2021 figure was $13.1 million, 5471.24% up from the prior year.
  • Other Non-Current Assets reached $13.1 million in Q4 2021 per SABSW's latest filing, up from $235111.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.1 million in Q4 2021 to a low of $235111.0 in Q4 2020.